蓝光膀胱镜在卡介苗治疗后膀胱癌复发检测中的效用:对临床试验招募和研究比较的启示
基于前瞻性多机构Cysview注册(2014-2019),分析282例接受BCG治疗后1年内行蓝光膀胱镜(BLC)的非肌层浸润性膀胱癌患者。总体复发率45.0%,仅用白光膀胱镜(WLC)会漏诊13%的复发,其中88%为原位癌。BLC辅助检测可提高复发检出,但假阳性率为5%。
要点
- BCG治疗后1年内行BLC,总体复发率45.0%。
- 仅用WLC会漏诊13%的复发,其中88%为原位癌。
- BLC假阳性率为5%,需与患者讨论假阳性风险。
核心结论
- BLC有助于检测近期BCG治疗后仅用WLC会漏诊的复发。
- 对接受BCG的高危患者应考虑使用BLC,并与患者讨论假阳性风险。
- BLC使用差异可能影响BCG无应答疾病临床试验的招募和比较。
研究设计与样本
- 前瞻性多机构Cysview注册研究(2014-2019)。
- 纳入BCG治疗后1年内行BLC的NMIBC患者,共282例膀胱镜检查。
主要发现
- 总体复发率为45.0%(127/282)。
- 仅用WLC会漏诊13%(16/127)的复发,即5.7%(16/282)的膀胱镜检查复发仅由BLC发现。
- WLC漏诊的16例复发中,88%(14例)为原位癌。
- 膀胱镜水平BLC假阳性率为5%(15/282)。
临床怎么用
- 对接受BCG的高危NMIBC患者,考虑在治疗后膀胱镜检查中使用BLC以提高复发检出。
- 使用BLC前应与患者讨论假阳性风险。
- 在BCG无应答疾病的临床试验设计和比较中,需考虑BLC使用差异的影响。
局限性
- 研究基于Cysview注册数据,可能存在选择偏倚。
- 未明确BLC使用对长期结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The utility of blue light cystoscopy (BLC) in patients receiving bacillus Calmette-Guérin (BCG) during post-treatment cystoscopy is not well understood. Our objective was to determine if BLC improves recurrence detection in patients with non-muscle invasive bladder cancer (NMIBC) undergoing BCG. MATERIALS AND METHODS: Using the prospective multi-institutional Cysview® Registry (2014-2019), patients with NMIBC who received BCG within 1 year prior to BLC were identified. Primary outcomes were recurrences and whether lesions were detected on white light cystoscopy (WLC), BLC or both. We calculated the percentage of cystoscopies with recurrences that were missed with WLC alone. The cystoscopy-level BLC false-positive rate was the proportion of cystoscopies with biopsies only due to BLC suspicious lesions without recurrence. RESULTS: Of 1,703 BLCs, 282 cystoscopies were in the analytic cohort. The overall recurrence rate was 45.0% (127). With only WLC, 13% (16/127) of recurrences would have been missed as 5.7% (16/282) of cystoscopies performed had recurrence only identified with BLC. Among 16 patients with recurrence missed with WLC, 88% (14) had carcinoma in situ. The cystoscopy-level BLC false-positive rate was 5% (15). CONCLUSIONS: BLC helped detect recurrences after recent BCG that would have been missed with WLC alone. Providers should consider BLC for high-risk patients undergoing BCG and should discuss the risk of false-positives with these patients. As clinical trials of novel therapies for BCG-unresponsive disease increase and there are no clear guidelines on BLC use for post-treatment cystoscopies, it is important to consider how variable BLC use could affect enrollment in and comparisons of these studies.
引用
- Chappidi MR, Yang H, Meng MV, et al. Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons. J Urol. 2021. PMID: 34694916. doi:10.1097/JU.0000000000002308
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。